Guizhou Bailing Group Pharmaceutical (002424.SZ): The clinical trial application for Tangning Tongluo Tablets has been approved.
Guizhou Bailin (002424.SZ) announcement, the company's wholly-owned subsidiary Bailin Yuxiu (Zhuhai) Pharmaceutical Co., Ltd.
Guizhou Bailing Group Pharmaceutical (002424.SZ) announced that its wholly-owned subsidiary, Bailin Yuxiu (Zhuhai) Pharmaceutical Co., Ltd. (referred to as "Bailin Yuxiu"), has received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration (NMPA). The application for the clinical trial of Tangning Tongluo Tablets submitted by Bailin Yuxiu has been approved, allowing the product to be used in clinical trials for type 2 diabetes.
Related Articles

POWER XINCHEN (01148) will be temporarily suspended from trading starting October 16th, awaiting the publication of insider information.

AFFLUENT FDN (01757) will be temporarily suspended from trading starting from October 16th, pending the release of insider information.

POWER XINCHEN (01148) Will be temporarily suspended from trading starting from October 16th. The reason will be announced later.
POWER XINCHEN (01148) will be temporarily suspended from trading starting October 16th, awaiting the publication of insider information.

AFFLUENT FDN (01757) will be temporarily suspended from trading starting from October 16th, pending the release of insider information.

POWER XINCHEN (01148) Will be temporarily suspended from trading starting from October 16th. The reason will be announced later.
